FDA Grants Accelerated Approval for Alzheimer’s Drug Lecanemab

MRI brain of a dementia patient with left parietal atrophy asymmetry. Atthapon Raksthaput/Shutterstock

The U.S. Food and Drug Administration (FDA) on Friday granted accelerated approval for the experimental dementia drug lecanemab.

Lecanemab, which will be marketed as Leqembi, is the second of a new class of Alzheimer’s disease drugs that target the illness’s core pathophysiology, according to the FDA, which said the drug is a significant step forward in the ongoing battle to treat Alzheimer’s disease properly.